Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC (NASDAQ:GWPH) in a research note released on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the company. Maxim Group cut GW Pharmaceuticals PLC from a buy rating to a hold rating and set a $61.00 price target for the company. in a report on Tuesday. Zacks Investment Research cut GW Pharmaceuticals PLC from a buy rating to a hold rating in a report on Monday, July 24th. BidaskClub upgraded GW Pharmaceuticals PLC from a sell rating to a hold rating in a report on Wednesday, June 21st. ValuEngine upgraded GW Pharmaceuticals PLC from a sell rating to a hold rating in a report on Wednesday, June 21st. Finally, TheStreet cut GW Pharmaceuticals PLC from a c- rating to a d+ rating in a report on Wednesday, May 10th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $147.94.

GW Pharmaceuticals PLC (NASDAQ GWPH) opened at 101.75 on Tuesday. The stock’s market cap is $2.58 billion. The company has a 50-day moving average of $107.48 and a 200-day moving average of $113.40. GW Pharmaceuticals PLC has a 52 week low of $79.62 and a 52 week high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.73) by $0.34. The company had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same quarter in the prior year, the company earned ($0.05) EPS. On average, analysts predict that GW Pharmaceuticals PLC will post ($5.28) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “GW Pharmaceuticals PLC (NASDAQ:GWPH) Given a $208.00 Price Target by Cantor Fitzgerald Analysts” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://theolympiareport.com/2017/08/12/gw-pharmaceuticals-plc-nasdaqgwph-given-a-208-00-price-target-by-cantor-fitzgerald-analysts.html.

Institutional investors have recently added to or reduced their stakes in the stock. Creative Planning boosted its position in GW Pharmaceuticals PLC by 179.3% in the first quarter. Creative Planning now owns 2,497 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 1,603 shares during the period. Bank of Montreal Can boosted its position in GW Pharmaceuticals PLC by 2,419.0% in the first quarter. Bank of Montreal Can now owns 2,519 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 2,419 shares during the period. Rothschild Investment Corp IL boosted its position in GW Pharmaceuticals PLC by 2.7% in the first quarter. Rothschild Investment Corp IL now owns 10,437 shares of the biopharmaceutical company’s stock valued at $1,262,000 after buying an additional 272 shares during the period. Candriam Luxembourg S.C.A. boosted its position in GW Pharmaceuticals PLC by 21.4% in the first quarter. Candriam Luxembourg S.C.A. now owns 17,000 shares of the biopharmaceutical company’s stock valued at $2,056,000 after buying an additional 3,000 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in GW Pharmaceuticals PLC during the first quarter valued at approximately $520,000. Institutional investors own 75.77% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.